The FDA has accepted Sanofi's New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor …
Sanofi
Lantus Insulin More Effective in Achieving Long Term Blood Sugar Control in Type 2 Diabetes Patients
New results presented by Sanofi at European Association for the Study of Diabetes (EASD) 48th Annual Meeting showed trea…
Lantus Does Not Increase Cancer Risk, New Studies Show
Sanofi has announced new results of a large-scale epidemiological program, conducted by independent researchers in the n…
Sanofi Presents New Data on Lixisenatide, an Investigational GLP-1 Agonist, for Type 2 Diabetes
Sanofi has presented data from two studies demonstrating Lyxumia (lixisenatide), a once-daily investigational GLP-1 agon…
Sanofi Launches iBGStar: New Blood Glucose Meter for iPhone
I was invited, along with several other diabetes patient online influencers, to Sanofi’s corporate office in Bridg…
